All In MedTech

Device Trial Radar · NCT03193021

AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID

AMBULATE: Multi-center, RCT for Safety & Efficacy of Cardiva Mid-Bore Venous VCS v. Manual Compression to Close Femoral Venotomies After Catheter-based Interventions Via 6-12F ID Sheaths With Single or Multiple Access Sites Per Limb

Last checked: Nov 21, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

204

Actual

Start

Sep 20, 2017

Primary completion

Apr 13, 2018

Study completion Apr 13, 2018

Sponsor

Lead sponsor
Cardiva Medical, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 20, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the trial is to demonstrate the safety and effectiveness of the Cardiva Mid-Bore Venous Vascular Closure System (VVCS) in sealing femoral venous access sites and providing reduced times to ambulation (TTA) compared with manual compression at the completion of catheter-based procedures performed through 6 - 12 Fr introducer sheaths.

Conditions

  • Surgical Wound

Interventions

  • Cardiva Mid-Bore VVCSDevice

    The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.

  • Manual compressionOther

    Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Ambulation (TTA)Time frame: Post-procedure, usually within 6 hours

1 more outcomes with a free account

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Heart & Vascular

    Anchorage, Alaska

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.